MCID: DGN002
MIFTS: 31

Degenerative Myopia

Categories: Eye diseases, Neuronal diseases

Aliases & Classifications for Degenerative Myopia

MalaCards integrated aliases for Degenerative Myopia:

Name: Degenerative Myopia 12 15 32
Myopia, Degenerative 44 70
Pathological Myopia 12 17
Degenerative Progressive High Myopia 12
Progressive High Myopia 12
Progressive High Myopia 12

Classifications:



External Ids:

Disease Ontology 12 DOID:11829
ICD9CM 34 360.21
MeSH 44 D047728
NCIt 50 C157149
SNOMED-CT 67 32022003
ICD10 32 H44.2
UMLS 70 C0154778

Summaries for Degenerative Myopia

MalaCards based summary : Degenerative Myopia, also known as myopia, degenerative, is related to yemenite deaf-blind hypopigmentation syndrome and central serous chorioretinopathy. An important gene associated with Degenerative Myopia is BLID (BH3-Like Motif Containing, Cell Death Inducer). The drugs Verteporfin and Atropine have been mentioned in the context of this disorder. Affiliated tissues include eye, retina and endothelial.

Wikipedia : 73 Near-sightedness, also known as short-sightedness and myopia, is an eye disorder where light focuses in... more...

Related Diseases for Degenerative Myopia

Diseases related to Degenerative Myopia via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 50)
# Related Disease Score Top Affiliating Genes
1 yemenite deaf-blind hypopigmentation syndrome 30.4 VEGFA CFH
2 central serous chorioretinopathy 29.8 CFH ARMS2
3 angioid streaks 29.6 VEGFA CFH ARMS2
4 macular degeneration, age-related, 1 29.3 VEGFA COL8A1 CFH ARMS2
5 myopia 29.1 ZNF644 VEGFA SHISA6 SCO2 RASGRF1 PRSS56
6 fundus dystrophy 29.0 ZNF644 VEGFA SHISA6 PRSS56 CFH ARMS2
7 refractive error 28.1 ZNF644 SHISA6 SCO2 RASGRF1 PRSS56 KCNQ5
8 retinal detachment 10.3
9 deafness and myopia 10.2 ZNF644 PRSS56
10 microvascular complications of diabetes 5 10.2
11 cycloplegia 10.1 SCO2 PRSS56
12 macular holes 10.1
13 retinoschisis 1, x-linked, juvenile 10.0
14 cataract 10.0
15 multifocal choroiditis 10.0 CFH ARMS2
16 basal laminar drusen 10.0 CFH ARMS2
17 anisometropia 10.0 ZNF644 SCO2 NDUFAF7 LUM
18 myopia 12, autosomal dominant 10.0
19 scleral staphyloma 10.0
20 retinal drusen 10.0 CFH ARMS2
21 macular retinal edema 10.0 VEGFA CFH
22 inherited retinal disorder 9.9
23 bullous retinoschisis 9.9 VEGFA CFH ARMS2
24 choroiditis 9.9 VEGFA CFH ARMS2
25 histoplasmosis 9.9 CFH ARMS2
26 kuhnt-junius degeneration 9.9 VEGFA CFH ARMS2
27 degeneration of macula and posterior pole 9.9 VEGFA CFH ARMS2
28 glaucoma, primary open angle 9.9
29 sinus node disease and myopia 9.9
30 intraocular pressure quantitative trait locus 9.9
31 open-angle glaucoma 9.9
32 sick sinus syndrome 9.9
33 endophthalmitis 9.9
34 myopic macular degeneration 9.9
35 fatal infantile cardioencephalomyopathy due to cytochrome c oxidase deficiency 9.9 SCO2 NDUFAF7
36 eye degenerative disease 9.9 VEGFA CFH ARMS2
37 complement component 2 deficiency 9.9 SCO2 CFH ARMS2
38 sensory system disease 9.8 VEGFA CFH ARMS2
39 dowling-degos disease 1 9.8
40 myopia 6 9.8
41 suppression amblyopia 9.8
42 amblyopia 9.8
43 hypopyon 9.8
44 optic nerve disease 9.8
45 vasculitis 9.8
46 vitreous detachment 9.8
47 cataract-glaucoma 9.8
48 contractures, pterygia, and spondylocarpotarsal fusion syndrome 1a 9.8 VEGFA CFH ARMS2
49 doyne honeycomb retinal dystrophy 9.8 CFH ARMS2
50 autosomal genetic disease 9.8 VEGFA CFH ARMS2

Graphical network of the top 20 diseases related to Degenerative Myopia:



Diseases related to Degenerative Myopia

Symptoms & Phenotypes for Degenerative Myopia

Drugs & Therapeutics for Degenerative Myopia

Drugs for Degenerative Myopia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 30)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Verteporfin Approved, Investigational Phase 3 129497-78-5
2
Atropine Approved, Vet_approved Phase 2, Phase 3 5908-99-6, 51-55-8 174174
3 Photosensitizing Agents Phase 3
4 Dermatologic Agents Phase 3
5 Pharmaceutical Solutions Phase 2, Phase 3
6 Ophthalmic Solutions Phase 2, Phase 3
7 Respiratory System Agents Phase 2, Phase 3
8 Anti-Arrhythmia Agents Phase 2, Phase 3
9 Anti-Asthmatic Agents Phase 2, Phase 3
10 Parasympatholytics Phase 2, Phase 3
11 Cholinergic Agents Phase 2, Phase 3
12 Cholinergic Antagonists Phase 2, Phase 3
13 Anesthetics Phase 2, Phase 3
14 Muscarinic Antagonists Phase 2, Phase 3
15 Mydriatics Phase 2, Phase 3
16 Neurotransmitter Agents Phase 2, Phase 3
17 Bronchodilator Agents Phase 2, Phase 3
18 Combretastatin Investigational Phase 2 82855-09-2
19
Fosbretabulin Investigational Phase 2 222030-63-9 5351387
20 Antimitotic Agents Phase 2
21 Tubulin Modulators Phase 2
22
Bevacizumab Approved, Investigational Phase 1 216974-75-3
23 Antineoplastic Agents, Immunological Phase 1
24
Ketorolac Approved 74103-06-3, 66635-83-4 3826
25
Triamcinolone Approved, Vet_approved 124-94-7 31307
26
Ranibizumab Approved 347396-82-1 459903
27 Triamcinolone hexacetonide
28 Triamcinolone diacetate
29 triamcinolone acetonide
30 Angiogenesis Inhibitors

Interventional clinical trials:

(show all 35)
# Name Status NCT ID Phase Drugs
1 The Safety and Efficacy of Conbercept in the Treatment of Choroidal Neovascularization (CNV) Secondary to High Myopia Unknown status NCT01809223 Phase 3 conbercept, Fixed;conbercept, PRN
2 A 12-month, Open-label, Interventional, Multicentre Study to Investigate the Current Criteria Driving Re-treatment With Ranibizumab Upon Relapse in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia Completed NCT02034006 Phase 3 Ranibizumab
3 A 12 Month, Phase III, Randomized, Double-masked, Multicenter, Active-controlled Study to Evaluate the Efficacy and Safety of Two Different Dosing Regimens of 0.5 mg Ranibizumab vs. Verteporfin PDT in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia Completed NCT01217944 Phase 3 Ranibizumab;Verteporfin PDT;Sham Ranibizumab;Sham verteporfin PDT
4 A Phase-3, Multi-center, Randomized, Double-masked, Sham-controlled Study of the Efficacy, Safety, and Tolerability of Intravitreal VEGF Trap-Eye in Subjects With Choroidal Neovascularization Secondary to Pathologic Myopia Completed NCT01249664 Phase 3
5 A 12-month, Phase III, Randomized, Double-masked, Multicenter, Active-controlled Study to Evaluate the Efficacy and Safety of Two Individualized Regimens of 0.5mg Ranibizumab vs. Verteporfin PDT in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia Completed NCT01922102 Phase 3 Ranibizumab 0.5mg;Ranibizumab 0.5 mg;Verteporfin PDT
6 Low-dose AtropIne for Myopia Control in Children, a Prospective, Double-blind, Placebo-controlled, Multicentric, Randomized Clinical Trial Not yet recruiting NCT03865160 Phase 2, Phase 3 Atropine eye drops, 0.01%;Placebo (NaCl 0.9%) eye drops
7 A Phase III, Randomized, Double-masked, Placebo-controlled, Parallel-group, Multicenter Study of the Safety and Efficacy of OT-101 (Atropine Sulfate 0.01%) in Treating the Progression of Myopia in Pediatric Subjects Not yet recruiting NCT04770610 Phase 3 OT-101 Ophthalmic Solution;Vehicle
8 A Phase II, Open-label, Multicentre, 12 Month Study to Evaluate the Efficacy and Safety of Ranibizumab (0.5mg) in Patients With Choroidal Neovascularisation Secondary to Pathological Myopia (PM) Completed NCT01037348 Phase 2 ranibizumab 0.5mg
9 A Phase II, Dose Ranging, Multi-Center Study to Evaluate the Safety and Efficacy of Combretastatin A4 Phosphate for Treating Subfoveal Choroidal Neovascularization in Subjects With Pathologic Myopia Completed NCT01423149 Phase 2 Combretastatin A-4 Phosphate
10 Treatment of Exudative and Vasogenic Chorioretinal Diseases Including Variants of AMD and Other CNV Related Maculopathy With Intravitreal Injection of Lucentis (Ranibizumab Injection) Completed NCT00470977 Phase 1, Phase 2 ranibizumab injection (0.5 mg)
11 Reduced-fluence Verteporfin Photodynamic Therapy Plus Ranibizumab for Choroidal Neovascularization in Pathologic Myopia: 48 Weeks Study Results Completed NCT01968486 Phase 1 PDT standard fluence, ranibizumab;PDT reduced fluence, ranibizumab;ranibizumab
12 An Open-Label, Pilot Study of Bevacizumab in Subjects With Choroidal Neovascularization Secondary to Diseases Other Than Age-Related Macular Degeneration Completed NCT00407719 Phase 1 Bevacizumab
13 Efficacy of Combining Intravitreal Bevacizumab With Photodynamic Therapy Using Reduced Light Fluence Rate in Choroidal Neovascularization Secondary to Pathologic Myopia. Completed NCT00802126 Phase 1 Combination therapy "IVB + rf-PDT"
14 Genomewide Screening of Pathological Myopia Unknown status NCT00155753
15 Eye Drops Study for Myopia Control in Schoolchildren Unknown status NCT03402100 eye drops
16 Early Vitrectomy for Macular Tractional Maculopathy. Multicenter Clinical Trial Unknown status NCT01121978
17 Randomized Controlled Trial of Different Lens Treatments on Chinese Adolescent Myopia Unknown status NCT02001415
18 Pharmacogenomic Study on Anti-VEGF Medicine in Treatment of Macular Neovascular Diseases Unknown status NCT03128463 Intravitreal injection of conbercept
19 Classification of Retinal Diseases by Artificial Intelligence Completed NCT04678375
20 Evaluation de la gêne Oculaire après Injections intravitréennes Completed NCT02806830 Optive
21 Myopia Control With Orthokeratology Contact Lenses in Spain Completed NCT04806763
22 Long-term Efficacy of Orthokeratology Contact Lens Wear in Controlling the Progression of Childhood Myopia Completed NCT04806698
23 Eleven Years of Menicon Z Night Contact Lens Wear in Reducing Myopia Progression in Children Completed NCT04806711
24 High Myopia: Extended and Longterm Observation of Pathologic Myopia Patients With the Risk for Developing a Myopic Choroidal Neovascularization (CNV) Completed NCT03070717
25 Collaborative Ocular Antiangiogenic Study of Ukraine. Multicentral, Open-label, Randomized, Prospective Study of Antiangiogenic Therapy of Choroidal Neovascularisation Associated With Myopia Recruiting NCT03963596
26 A Sub-Study to Assess the Choroidal Response to Novel Spectacle Lens to Control Myopia Progression (CHERRY) Active, not recruiting NCT03818880
27 Myopia Progression in Children and Adolescents Before and After Use of a Novel Extended Depth of Focus Daily Disposable Soft Contact Lens Active, not recruiting NCT03358862
28 Does Specialty Soft Contact Lens Wear Decrease the Onset and Progression of Myopia in Optometry School Interns? Active, not recruiting NCT04334369
29 Randomized Clinical Trial on Atropine 0.01% for the Control of Myopia in Omani Children Enrolling by invitation NCT03508817 Early Phase 1 Atropine Sulfate 0.01% Eye Drops
30 Punctate Inner Choroidopathy (PIC) and Its Role in Progression of Pathological Myopia Not yet recruiting NCT04561869
31 Clinical Research of Human Retinal Pigment Epithelial (HuRPE) Cell Injection on Atrophy of High Myopia Macular Area Not yet recruiting NCT04212624
32 OCTA to Quantify the Parapapillary Choroidal Microvascular Changes in High Myopia Not yet recruiting NCT04255524
33 The Multicenter Randomized Clinical Trial of Fast-progressing Myopia Control Using Repeated Low-Level Red-Light Therapy and Orthokeratology Not yet recruiting NCT04722874
34 Myopia Progression in Children Wearing Near Center and Distance Center Multifocals - a Randomized Controlled Clinical Trial Withdrawn NCT03519490
35 A Clinical Trial to Study the Efficacy and Safety of Intravitreal Pegaptanib in Treatment of Choroidal Neovascularisation Secondary to Pathologic Myopia Withdrawn NCT01218230 Intravitreal Pegaptanib

Search NIH Clinical Center for Degenerative Myopia

Cochrane evidence based reviews: myopia, degenerative

Genetic Tests for Degenerative Myopia

Anatomical Context for Degenerative Myopia

MalaCards organs/tissues related to Degenerative Myopia:

40
Eye, Retina, Endothelial

Publications for Degenerative Myopia

Articles related to Degenerative Myopia:

(show top 50) (show all 340)
# Title Authors PMID Year
1
Update and guidance on management of myopia. European Society of Ophthalmology in cooperation with International Myopia Institute. 61
33673740 2021
2
Choroidal neovascularization secondary to pathological myopia-macular Bruch membrane defects as prognostic factor to anti-VEGF treatment. 61
33744983 2021
3
Intravitreal conbercept for choroidal neovascularisation secondary to pathological myopia in a real-world setting in China : Intravitreal conbercept was safe and effective in treating myopic choroidal neovascularization. 61
33663431 2021
4
Long-term progression of myopic maculopathy in degenerative myopia as imaged by SD-OCT and IR imaging. 61
33689624 2021
5
Pathological myopia classification with simultaneous lesion segmentation using deep learning. 61
33412285 2021
6
Prevalence of fundus tessellation and its associated factors in Chinese children and adolescents with high myopia. 61
33629538 2021
7
Sensitivity and Specificity of Multispectral Imaging For Polypoidal Choroidal Vasculopathy. 61
33512897 2021
8
Immediate post partum macular subretinal bleeding in a highly myopic patient: a case report. 61
33478418 2021
9
Comparison of structural and functional outcome of aflibercept versus ranibizumab in patients with myopic choroidal neovascularization. 61
31690105 2021
10
Gradual healing of macular retinoschisis after photodynamic therapy for choroidal neovascularization in pathological myopia eyes. 61
32977067 2020
11
DeepUWF: An Automated Ultra-wide-field Fundus Screening System via Deep Learning. 61
33361011 2020
12
The Evaluation of a Two-Year Outcome of Intravitreal Conbercept versus Ranibizumab for Pathological Myopic Choroidal Neovascularization. 61
32191134 2020
13
Quantitative analysis with volume rendering of pathological myopic eyes by high-resolution three-dimensional magnetic resonance imaging. 61
33080714 2020
14
"Macular sink hole" with intrachoroidal cavitation in a case of pathological myopia. 61
32971699 2020
15
In Vivo Visualization of Eye Vasculature Using Super-Resolution Ultrasound Microvessel Imaging. 61
32054567 2020
16
Retinoschisis: splitting hairs on retinal splitting. 61
31663163 2020
17
Deep learning for automated glaucomatous optic neuropathy detection from ultra-widefield fundus images. 61
32938630 2020
18
Heavy Eye Syndrome Mimicking Abducens Nerve Palsies. 61
32345394 2020
19
Optical coherence tomography angiography in myopic peripapillary intrachoroidal cavitation complicated by choroidal neovascularization. 61
32674595 2020
20
Three-dimensional choroidal vessel network quantification using swept source optical coherence tomography. 61
33018368 2020
21
Large choroidal excavation in myopic macular degeneration: A case report. 61
32664753 2020
22
Quantitative assessment of the retinal microvasculature and choriocapillaris in myopic patients using swept-source optical coherence tomography angiography. 61
32144487 2020
23
Structural profile of dome-shaped macula in degenerative myopia and its association with macular disorders. 61
32448138 2020
24
Deep Retinal Capillary Plexus Decreasing Correlated With the Outer Retinal Layer Alteration and Visual Acuity Impairment in Pathological Myopia. 61
32343783 2020
25
Management of coexistent choroidal neovascular membrane and macular hole with serous detachment in a case of pathological myopia: challenges and dilemmas. 61
32234863 2020
26
Pathological myopia-induced antioxidative proteins in the vitreous humor. 61
32309340 2020
27
Serum Metabolomics Reveals Personalized Metabolic Patterns for Macular Neovascular Disease Patient Stratification. 61
31755721 2020
28
Association between birth weight and refractive error in adulthood: a Mendelian randomisation study. 61
31097437 2020
29
Oculocardiac Reflex During Intravitreal Injection. 61
32490017 2020
30
Peripheral retinal neovascularization secondary to highly myopic superficial Retinoschisis: a case report. 61
31931752 2020
31
Intrachoroidal cavitation in myopic eyes. 61
31300972 2020
32
Pathogenesis and Prevention of Worsening Axial Elongation in Pathological Myopia. 61
32256044 2020
33
Increased Levels of DKK1 in Vitreous Fluid of Patients with Pathological Myopia and the Correlation between DKK1 Levels and Axial Length. 61
31335221 2020
34
Using optical coherence tomography angiography to guide the treatment of pathological myopic patients with submacular hemorrhage. 61
31470121 2019
35
Novel mutations of RPGR in Chinese families with X-linked retinitis pigmentosa. 61
31775781 2019
36
[Strengthening the understanding of the pathological evolution of myopia]. 61
31607061 2019
37
[Research progress of treatment strategies for choroidal neovascularization secondary to pathological myopia]. 61
31607068 2019
38
Scleral rupture during intraoperative silicone oil injection in pars plana vitrectomy. 61
31312752 2019
39
Prevalence and Associations of Posterior Segment Manifestations in a Cohort of Egyptian Patients with Pathological Myopia. 61
30964360 2019
40
Ultra-Widefield Retinal Imaging for Analyzing the Association Between Types of Pathological Myopia and Posterior Staphyloma. 61
31547036 2019
41
Generation of an integration-free induced pluripotent stem cell line (FDEENTi003-A) from a patient with pathological myopia. 61
31376721 2019
42
Macular retinal thickness and flow density change by optical coherence tomography angiography after posterior scleral reinforcement. 61
30929195 2019
43
Macular hole retinal detachment after intravitreal Conbercept injection for the treatment of choroidal neovascularization secondary to degenerative myopia: a case report. 61
31331298 2019
44
Visual Acuity in Pathological Myopia Is Correlated With the Photoreceptor Myoid and Ellipsoid Zone Thickness and Affected by Choroid Thickness. 61
31013344 2019
45
Effects of posterior scleral reinforcement in pathological myopia: a 3-year follow-up study. 61
30554267 2019
46
Riboflavin-induced Type 1 photo-oxidation of tryptophan using a high intensity 365 nm light emitting diode. 61
30502456 2019
47
Ranibizumab for the treatment of choroidal neovascularization due to cause other than age related macular degeneration. 61
31779462 2019
48
Establishment of an induced pluripotent stem cell line (FDEENTi001-A) from a patient with pathological myopia. 61
30611020 2019
49
Long-Term Natural Course of Pathologic Myopia in Chinese Patients. 61
31016036 2019
50
Retardation of Myopia Progression by Multifocal Soft Contact Lenses. 61
30745799 2019

Variations for Degenerative Myopia

Expression for Degenerative Myopia

Search GEO for disease gene expression data for Degenerative Myopia.

Pathways for Degenerative Myopia

GO Terms for Degenerative Myopia

Biological processes related to Degenerative Myopia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 camera-type eye morphogenesis GO:0048593 8.62 VEGFA COL8A1

Sources for Degenerative Myopia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....